These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 37877561)
21. Clinico-social factors to choose radioactive iodine dose in differentiated thyroid cancer patients: an Asian survey. Jabin Z; Kwon SY; Bom HS; Lin Y; Yang K; Inaki A; Dewi AR; Al-Ibraheem AN; Balooshi BA; San Luis TOL; Nucl Med Commun; 2018 Apr; 39(4):283-289. PubMed ID: 29381585 [TBL] [Abstract][Full Text] [Related]
30. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study. Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902 [TBL] [Abstract][Full Text] [Related]
31. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014 [TBL] [Abstract][Full Text] [Related]
32. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Sawka AM; Brierley JD; Tsang RW; Thabane L; Rotstein L; Gafni A; Straus S; Goldstein DP Endocrinol Metab Clin North Am; 2008 Jun; 37(2):457-80, x. PubMed ID: 18502337 [TBL] [Abstract][Full Text] [Related]
33. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma. Corrêa NL; de Sá LV; de Mello RC Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670 [TBL] [Abstract][Full Text] [Related]
34. [Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer]. Gawkowska-Suwińska M; Turska M; Roskosz J; Puch Z; Jurecka-Tuleja B; Handkiewicz-Junak D; Wygoda Z; Jarzab B Wiad Lek; 2001; 54 Suppl 1():278-88. PubMed ID: 12182036 [TBL] [Abstract][Full Text] [Related]
35. Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin. Watanabe K; Igarashi T; Uchiyama M; Ojiri H Ann Nucl Med; 2020 Dec; 34(12):920-925. PubMed ID: 32940889 [TBL] [Abstract][Full Text] [Related]
36. Whole-remnant and maximum-voxel SPECT/CT dosimetry in Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713 [TBL] [Abstract][Full Text] [Related]
37. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine. Kluijfhout WP; Pasternak JD; Drake FT; Beninato T; Shen WT; Gosnell JE; Suh I; C L; Duh QY Surgery; 2017 Jan; 161(1):127-133. PubMed ID: 27855968 [TBL] [Abstract][Full Text] [Related]
38. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781 [TBL] [Abstract][Full Text] [Related]
39. Radioactive iodine in differentiated thyroid cancer: a national database perspective. Orosco RK; Hussain T; Noel JE; Chang DC; Dosiou C; Mittra E; Divi V; Orloff LA Endocr Relat Cancer; 2019 Oct; 26(10):795-802. PubMed ID: 31443087 [TBL] [Abstract][Full Text] [Related]
40. Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. Deandreis D; Rubino C; Tala H; Leboulleux S; Terroir M; Baudin E; Larson S; Fagin JA; Schlumberger M; Tuttle RM J Nucl Med; 2017 May; 58(5):717-722. PubMed ID: 27738010 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]